Go Pro
→ SPCX Warning - and Worst News for Stocks in 50 Years (From TradeSmith) (Ad)tc pixel Free FATE Stock Alerts

Fate Therapeutics (FATE) Financials

Fate Therapeutics logo
$2.92 -0.10 (-3.31%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$2.94 +0.02 (+0.86%)
As of 07/2/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Fate Therapeutics

Annual Income Statements for Fate Therapeutics

This table shows Fate Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -30 -33 -43 -67 -98 -173 -212 -282 -161 -186 -136
Consolidated Net Income / (Loss)		 -30 -33 -43 -67 -98 -173 -212 -282 -161 -186 -136
Net Income / (Loss) Continuing Operations		 -30 -33 -43 -66 -98 -173 -212 -282 -161 -186 -136
Total Pre-Tax Income 		-30 -33 -43 -66 -98 -173 -212 -282 -161 -186 -136
Total Operating Income		 -28 -32 -42 -67 -101 -128 -217 -308 -191 -210 -148
Total Gross Profit		 2.43 4.40 4.11 4.74 11 31 56 96 64 14 6.65
Total Revenue		 2.43 4.40 4.11 4.74 11 31 56 96 64 14 6.65
Operating Revenue		 2.43 4.40 4.11 4.74 11 31 56 96 64 14 6.65
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 30 36 46 72 111 160 273 405 254 224 154
Selling, General & Admin Expense		 10 9.91 12 16 24 34 57 84 81 74 47
Research & Development Expense		 20 26 34 56 88 126 216 320 173 135 108
Impairment Charge		 - - - - - - - - 0.00 15 0.00
Total Other Income / (Expense), net		 -2.21 -1.50 -0.83 0.99 2.58 -45 4.84 27 30 24 11
Interest & Investment Income		 0.01 0.14 0.56 2.19 4.33 2.40 1.31 5.84 17 17 11
Other Income / (Expense), net		 - - - 0.49 0.00 -48 3.53 21 12 6.73 0.34
Basic Earnings per Share		 ($1.18) ($1.05) ($1.02) ($1.19) ($1.44) ($2.10) ($2.24) ($2.91) ($1.64) ($1.64) ($1.15)
Weighted Average Basic Shares Outstanding		 25.48M 31.75M 41.98M 56.20M 68.19M 82.39M 94.75M 96.83M 98.41M 113.69M 118.79M
Diluted Earnings per Share		 ($1.18) ($1.05) ($1.02) ($1.19) ($1.44) ($2.10) ($2.24) ($2.91) ($1.64) ($1.64) ($1.15)
Weighted Average Diluted Shares Outstanding		 25.48M 31.75M 41.98M 56.20M 68.19M 82.39M 94.75M 96.83M 98.41M 113.69M 118.79M
Weighted Average Basic & Diluted Shares Outstanding		 25.48M 31.75M 41.98M 56.20M 68.19M 82.39M 94.75M 98.16M 99.24M 114.60M 116.26M

Quarterly Income Statements for Fate Therapeutics

This table shows Fate Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -45 -44 -48 -38 -48 -52 -38 -34 -32 -32 -31
Consolidated Net Income / (Loss)		 -45 -44 -48 -38 -48 -52 -38 -34 -32 -32 -31
Net Income / (Loss) Continuing Operations		 -45 -44 -48 -38 -48 -52 -38 -34 -32 -32 -31
Total Pre-Tax Income 		-45 -44 -48 -38 -48 -52 -38 -34 -32 -32 -31
Total Operating Income		 -51 -48 -51 -45 -52 -62 -41 -37 -35 -35 -33
Total Gross Profit		 1.94 1.68 1.93 6.77 3.07 1.86 1.63 1.91 1.74 1.37 1.30
Total Revenue		 1.94 1.68 1.93 6.77 3.07 1.86 1.63 1.91 1.74 1.37 1.30
Operating Revenue		 1.94 1.68 1.93 6.77 3.07 1.86 1.63 1.91 1.74 1.37 1.30
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 53 50 53 52 55 64 43 39 36 36 34
Selling, General & Admin Expense		 19 18 21 17 21 15 14 11 11 11 9.60
Research & Development Expense		 34 32 32 35 35 34 29 27 26 25 25
Total Other Income / (Expense), net		 6.11 3.95 3.06 6.66 4.70 9.60 3.66 2.90 2.49 2.35 1.79
Interest & Investment Income		 4.70 4.41 4.15 4.83 4.44 3.87 3.34 2.92 2.58 2.22 1.87
Other Income / (Expense), net		 1.41 -0.46 -1.09 1.83 0.26 5.72 0.32 -0.02 -0.09 0.13 -0.08
Basic Earnings per Share		 ($0.46) ($0.45) ($0.47) ($0.33) ($0.40) ($0.44) ($0.32) ($0.29) ($0.27) ($0.27) ($0.26)
Weighted Average Basic Shares Outstanding		 98.57M 98.41M 101.10M 117.47M 117.77M 113.69M 118.38M 118.53M 119.00M 118.79M 120.03M
Diluted Earnings per Share		 ($0.46) ($0.45) ($0.47) ($0.33) ($0.40) ($0.44) ($0.32) ($0.29) ($0.27) ($0.27) ($0.26)
Weighted Average Diluted Shares Outstanding		 98.57M 98.41M 101.10M 117.47M 117.77M 113.69M 118.38M 118.53M 119.00M 118.79M 120.03M
Weighted Average Basic & Diluted Shares Outstanding		 98.60M 99.24M 113.83M 113.88M 113.89M 114.60M 114.63M 115.33M 115.35M 116.26M 116.56M

Annual Cash Flow Statements for Fate Therapeutics

This table details how cash moves in and out of Fate Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 16 24 0.34 102 -91 83 -34 -72 -20 -11 11
Net Cash From Operating Activities		 -18 -30 -37 -39 -83 -39 -163 -248 -132 -123 -106
Net Cash From Continuing Operating Activities		 -18 -30 -37 -39 -83 -39 -163 -248 -132 -123 -106
Net Income / (Loss) Continuing Operations		 -30 -33 -43 -67 -98 -173 -212 -282 -161 -186 -136
Consolidated Net Income / (Loss)		 -30 -33 -43 -67 -98 -173 -212 -282 -161 -186 -136
Depreciation Expense		 0.69 0.88 0.97 1.20 2.19 3.09 5.85 14 18 19 13
Amortization Expense		 0.18 0.31 0.06 -0.22 0.26 4.79 9.06 2.42 -4.20 -9.08 -3.61
Non-Cash Adjustments To Reconcile Net Income		 10 3.67 5.13 13 17 147 35 58 -6.01 56 22
Changes in Operating Assets and Liabilities, net		 0.37 -1.22 -0.02 14 -4.89 -21 -0.31 -40 21 -2.85 -1.24
Net Cash From Investing Activities		 -1.50 -4.11 -10 -0.46 -157 -161 -324 167 113 12 111
Net Cash From Continuing Investing Activities		 -1.50 -4.11 -10 -0.46 -157 -161 -324 167 113 12 111
Purchase of Property, Plant & Equipment		 -1.50 -0.46 -1.73 -2.30 -7.40 -4.93 -51 -36 -6.15 -0.73 -5.95
Purchase of Investments		 0.00 -20 -40 -56 -249 -277 -968 -405 -359 -318 -195
Sale of Property, Plant & Equipment		 0.00 0.02 - - - - - - - 0.00 0.36
Sale and/or Maturity of Investments		 0.00 16 32 58 99 121 695 607 478 331 312
Net Cash From Financing Activities		 36 58 47 141 150 283 453 9.21 0.09 100 5.49
Net Cash From Continuing Financing Activities		 36 58 47 141 150 283 453 9.21 0.09 100 5.49
Issuance of Common Equity		 37 65 43 135 162 239 432 - 0.00 95 0.00
Other Financing Activities, net		 0.42 0.19 0.21 6.20 2.52 44 21 9.21 0.09 5.37 5.49

Quarterly Cash Flow Statements for Fate Therapeutics

This table details how cash moves in and out of Fate Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -13 8.54 79 -84 -3.96 -1.85 8.86 -3.67 -0.63 6.01 -7.24
Net Cash From Operating Activities		 -38 -37 -33 -32 -29 -28 -34 -25 -24 -23 -31
Net Cash From Continuing Operating Activities		 -38 -37 -33 -32 -29 -28 -34 -25 -24 -23 -31
Net Income / (Loss) Continuing Operations		 -45 -44 -48 -38 -48 -52 -38 -34 -32 -32 -31
Consolidated Net Income / (Loss)		 -45 -44 -48 -38 -48 -52 -38 -34 -32 -32 -31
Depreciation Expense		 4.74 4.89 4.82 4.72 4.61 4.81 3.33 3.28 3.23 3.06 2.92
Amortization Expense		 -3.26 -2.91 -2.63 -2.72 -2.20 -1.53 -1.07 -0.85 -0.81 -0.88 -0.77
Non-Cash Adjustments To Reconcile Net Income		 8.68 -32 12 7.23 12 19 6.31 7.80 4.95 2.93 3.68
Changes in Operating Assets and Liabilities, net		 -3.27 37 0.09 -3.11 3.61 1.87 -4.77 -0.75 0.51 3.95 -5.43
Net Cash From Investing Activities		 25 45 17 -53 25 23 43 20 21 28 24
Net Cash From Continuing Investing Activities		 25 45 17 -53 25 23 43 20 21 28 24
Purchase of Property, Plant & Equipment		 -0.57 -0.18 -0.09 -0.05 -0.50 -0.10 -1.20 -1.36 -2.20 -1.19 -0.24
Purchase of Investments		 -102 -50 -86 -129 -65 -38 -49 -51 -58 -38 -29
Sale and/or Maturity of Investments		 128 96 104 75 91 61 92 72 81 66 53
Net Cash From Financing Activities		 - -0.18 95 1.27 - 3.13 0.00 1.33 2.48 1.69 0.00
Net Cash From Continuing Financing Activities		 - -0.18 95 1.27 - 3.13 0.00 1.33 2.48 1.69 0.00
Issuance of Common Equity		 - - 95 -0.66 - - 0.00 - - - 0.00
Other Financing Activities, net		 - -0.18 0.30 1.94 - 3.13 0.00 1.33 2.48 1.69 0.00

Annual Balance Sheets for Fate Therapeutics

This table presents Fate Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 68 95 105 213 302 622 921 706 506 441 319
Total Current Assets		 66 93 103 205 227 494 633 502 332 292 209
Cash & Equivalents		 65 89 89 191 100 167 134 61 42 36 47
Short-Term Investments		 0.00 3.50 12 10 122 316 482 375 273 243 157
Accounts Receivable		 - - 0.00 0.50 0.00 5.52 8.68 38 1.83 3.54 0.92
Prepaid Expenses		 0.84 1.21 1.65 3.69 5.66 5.89 8.83 27 15 9.30 4.13
Plant, Property, & Equipment, net		 2.16 1.58 2.55 5.13 11 32 92 110 97 64 57
Total Noncurrent Assets		 0.15 0.15 0.02 2.48 64 96 197 93 78 84 53
Long-Term Investments		 - - - 0.00 39 0.00 101 4.94 0.98 28 1.47
Other Noncurrent Operating Assets		 0.02 0.02 0.02 2.48 24 96 96 89 77 57 52
Total Liabilities & Shareholders' Equity		 68 95 105 213 302 622 921 706 506 441 319
Total Liabilities		 30 22 28 53 58 238 243 222 138 122 112
Total Current Liabilities		 13 15 11 27 28 86 81 114 39 39 36
Accounts Payable		 1.00 0.93 1.68 4.21 5.82 6.28 8.61 8.27 4.72 9.37 2.66
Accrued Expenses		 2.44 3.96 7.25 11 15 16 42 54 28 21 20
Current Deferred Revenue		 2.46 2.11 2.12 7.59 2.79 21 21 42 0.69 0.39 0.38
Other Current Liabilities		 0.00 - 0.00 2.11 4.50 43 8.78 9.63 6.18 7.42 13
Total Noncurrent Liabilities		 16 6.71 17 25 30 152 161 108 99 83 76
Capital Lease Obligations		 - - - 0.00 25 94 - 104 97 78 73
Other Noncurrent Operating Liabilities		 0.80 1.28 0.18 1.95 0.70 12 134 3.86 1.35 5.60 2.40
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 38 73 77 160 245 384 679 484 368 319 207
Total Preferred & Common Equity		 38 73 77 160 245 384 679 484 368 319 207
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 38 73 77 160 245 384 679 484 368 319 207
Common Stock		 180 249 296 446 628 941 1,449 1,537 1,580 1,716 1,741
Retained Earnings		 -142 -176 -219 -285 -384 -557 -769 -1,051 -1,212 -1,398 -1,534
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.00 -0.00 -0.00 0.02 0.07 -0.76 -1.85 0.02 0.27 0.12

Quarterly Balance Sheets for Fate Therapeutics

This table presents Fate Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 544 570 529 495 399 372 344 285
Total Current Assets		 364 394 319 310 248 230 221 180
Cash & Equivalents		 33 121 37 38 45 41 41 40
Short-Term Investments		 316 262 268 259 196 182 175 135
Accounts Receivable		 1.54 0.86 1.05 4.13 2.41 1.40 0.68 0.70
Prepaid Expenses		 13 9.97 13 9.24 5.39 6.17 5.15 4.00
Plant, Property, & Equipment, net		 102 92 88 82 63 61 59 54
Total Noncurrent Assets		 78 83 122 102 88 80 63 51
Long-Term Investments		 0.00 7.60 47 34 32 26 10 0.00
Other Noncurrent Operating Assets		 78 76 75 69 55 54 53 51
Total Liabilities & Shareholders' Equity		 544 570 529 495 399 372 344 285
Total Liabilities		 141 144 132 133 110 110 110 105
Total Current Liabilities		 41 45 35 37 28 29 28 31
Accounts Payable		 5.71 6.77 5.50 6.35 4.19 4.04 3.50 3.28
Accrued Expenses		 29 32 23 24 17 18 18 14
Current Deferred Revenue		 1.11 0.16 0.00 0.60 0.21 0.00 0.01 0.58
Other Current Liabilities		 5.98 6.40 6.64 6.89 6.54 6.45 7.03 13
Total Noncurrent Liabilities		 100 98 97 95 82 82 81 75
Capital Lease Obligations		 99 96 94 92 77 76 74 72
Other Noncurrent Operating Liabilities		 0.70 2.74 3.12 3.14 5.32 5.92 7.00 2.48
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 403 426 397 362 288 261 234 180
Total Preferred & Common Equity		 403 426 397 362 288 261 234 180
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 403 426 397 362 288 261 234 180
Common Stock		 1,571 1,686 1,696 1,707 1,724 1,731 1,736 1,745
Retained Earnings		 -1,168 -1,260 -1,298 -1,346 -1,436 -1,470 -1,502 -1,566
Accumulated Other Comprehensive Income / (Loss)		 -0.50 -0.19 -0.42 0.84 0.19 0.06 0.15 -0.08

Annual Metrics And Ratios for Fate Therapeutics

This table displays calculated financial ratios and metrics derived from Fate Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 28,716,570.00 34,148,154.00 41,685,695.00 64,518,813.00 75,592,739.00 87,244,032.00 95,492,766.00 97,170,443.00 98,601,966.00 - 115,352,289.00
DEI Adjusted Shares Outstanding		 28,716,570.00 34,148,154.00 41,685,695.00 64,518,813.00 75,592,739.00 87,244,032.00 95,492,766.00 97,170,443.00 98,601,966.00 - 115,352,289.00
DEI Earnings Per Adjusted Shares Outstanding		 -1.04 -0.98 -1.03 -1.03 -1.30 -1.99 -2.22 -2.90 -1.63 - -1.18
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 81.08% -6.72% 15.44% 125.32% 194.33% 77.66% 72.44% -34.03% -78.55% -51.24%
EBITDA Growth		 -10.40% -14.31% -33.56% -59.65% -49.79% -70.86% -18.24% -36.68% 39.56% -18.07% 28.71%
EBIT Growth		 -11.56% -15.05% -31.79% -58.10% -51.25% -74.52% -21.43% -34.72% 38.06% -14.28% 27.60%
NOPAT Growth		 -11.56% -15.05% -31.79% -59.27% -50.13% -27.16% -69.41% -42.12% 38.22% -10.37% 29.76%
Net Income Growth		 -15.88% -11.57% -28.36% -55.05% -47.38% -76.66% -22.36% -32.79% 42.88% -15.74% 26.82%
EPS Growth		 7.09% 11.02% 2.86% -16.67% -21.01% -45.83% -6.67% -29.91% 43.64% 0.00% 29.88%
Operating Cash Flow Growth		 17.94% -62.11% -23.45% -4.98% -115.20% 52.84% -315.18% -52.40% 46.71% 7.10% 13.66%
Free Cash Flow Firm Growth		 31.96% -87.59% -27.25% -4.69% -249.12% 27.59% -55.69% -237.09% 65.88% 35.96% -1.67%
Invested Capital Growth		 -578.82% 3.04% -8.13% -185.22% 134.38% -150.89% -733.39% 488.17% 2.15% -39.95% -16.15%
Revenue Q/Q Growth		 79.41% -1.10% 0.00% 15.44% 11.96% 71.40% 2.14% 39.54% -40.18% 1.37% -6.88%
EBITDA Q/Q Growth		 -3.25% -2.51% -12.38% -6.42% -13.55% -41.70% -8.19% 3.84% 4.63% -3.30% 12.84%
EBIT Q/Q Growth		 -3.61% -2.38% -12.23% -6.40% -13.96% -42.03% -8.12% 3.58% 5.67% -3.82% 12.70%
NOPAT Q/Q Growth		 -3.61% -2.38% -12.23% -7.18% -13.96% -3.49% -19.88% 1.58% 7.90% -6.95% 15.47%
Net Income Q/Q Growth		 -4.21% -1.50% -11.87% -5.60% -14.29% -16.70% -7.89% 4.17% 7.07% -4.51% 12.67%
EPS Q/Q Growth		 6.35% 2.78% -9.68% 4.03% -10.77% -13.51% -4.67% 4.90% 7.34% 0.61% 12.88%
Operating Cash Flow Q/Q Growth		 -4.64% -1.99% -9.42% -0.78% -21.14% 11.05% -43.83% -2.10% 22.66% 6.71% 4.06%
Free Cash Flow Firm Q/Q Growth		 -0.64% -3.01% -9.90% -0.56% -18.18% 12.90% 22.09% -36.86% 29.17% 20.15% -9.38%
Invested Capital Q/Q Growth		 2.26% 3.90% -3.14% -14.39% 93.67% -182.58% -221.28% 40.72% -1.58% -27.47% -9.04%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -1,107.32% -699.05% -1,000.93% -1,384.20% -920.20% -534.18% -355.53% -281.81% -258.19% -1,420.79% -2,077.52%
Operating Margin		 -1,142.82% -726.10% -1,025.94% -1,415.44% -943.14% -407.47% -388.56% -320.23% -299.86% -1,542.63% -2,222.45%
EBIT Margin		 -1,142.82% -726.10% -1,025.94% -1,405.02% -943.14% -559.23% -382.23% -298.61% -280.35% -1,493.29% -2,217.38%
Profit (Net Income) Margin		 -1,233.73% -760.15% -1,046.08% -1,405.02% -919.00% -551.59% -379.89% -292.55% -253.30% -1,366.46% -2,051.08%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.75% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 107.95% 104.69% 101.96% 99.26% 97.44% 98.63% 99.39% 97.97% 90.35% 91.51% 92.50%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -4,104.35% 0.00% -397.02% -90.08% -122.93% -125.18%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% -4,077.55% 0.00% -384.53% -80.16% -105.48% -106.93%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 4,049.24% 0.00% 348.57% 52.31% 68.72% 73.34%
Return on Equity (ROE)		 -90.37% -60.19% -57.14% -56.05% -48.44% -55.11% -39.90% -48.46% -37.76% -54.21% -51.84%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% -1,183.40% 0.00% 0.00% -273.13% -92.20% -73.01% -107.61%
Operating Return on Assets (OROA)		 -46.64% -39.22% -42.05% -41.84% -39.09% -38.02% -27.65% -35.35% -29.40% -42.99% -38.80%
Return on Assets (ROA)		 -50.35% -41.06% -42.88% -41.84% -38.09% -37.50% -27.48% -34.63% -26.56% -39.34% -35.89%
Return on Common Equity (ROCE)		 -90.37% -60.19% -57.14% -56.04% -48.44% -55.11% -39.90% -48.46% -37.76% -54.21% -51.84%
Return on Equity Simple (ROE_SIMPLE)		 -78.85% -45.74% -55.65% -41.50% -40.10% -45.10% -31.25% -58.21% -43.68% -58.44% 0.00%
Net Operating Profit after Tax (NOPAT)		 -19 -22 -29 -47 -71 -90 -152 -216 -133 -147 -103
NOPAT Margin		 -799.98% -508.27% -718.16% -990.81% -660.20% -285.23% -271.99% -224.16% -209.90% -1,079.84% -1,555.71%
Net Nonoperating Expense Percent (NNEP)		 -27.64% -17.29% -16.05% -14.40% -13.09% -26.80% -10.90% -12.50% -9.91% -17.45% -18.25%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -28.63% -37.12% -36.86%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 425.83% 225.19% 289.16% 333.50% 221.32% 107.83% 102.64% 87.47% 128.20% 544.12% 699.99%
R&D to Revenue		 816.99% 600.91% 836.78% 1,181.94% 821.82% 399.64% 385.92% 332.77% 271.66% 990.40% 1,622.46%
Operating Expenses to Revenue		 1,242.82% 826.10% 1,125.94% 1,515.44% 1,043.14% 507.47% 488.56% 420.23% 399.86% 1,642.63% 2,322.45%
Earnings before Interest and Taxes (EBIT)		 -28 -32 -42 -67 -101 -176 -213 -288 -178 -204 -147
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -27 -31 -41 -66 -98 -168 -199 -271 -164 -194 -138
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.54 1.17 3.30 5.16 6.04 20.64 8.23 2.03 1.00 0.59 0.55
Price to Tangible Book Value (P/TBV)		 2.54 1.17 3.30 5.16 6.04 20.64 8.23 2.03 1.00 0.59 0.55
Price to Revenue (P/Rev)		 39.81 19.47 62.03 174.64 138.52 252.37 100.05 10.18 5.80 13.79 17.05
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 139.77 0.00 0.00 4.39 1.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 20.65 0.97 41.02 135.32 116.43 240.00 87.22 6.68 2.36 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.48 0.15 0.19 0.09 0.10 0.24 0.00 0.21 0.26 0.24 0.35
Long-Term Debt to Equity		 0.28 0.03 0.19 0.08 0.10 0.24 0.00 0.21 0.26 0.24 0.35
Financial Leverage		 -1.15 -1.15 -1.12 -1.15 -1.04 -0.99 -1.04 -0.91 -0.65 -0.65 -0.69
Leverage Ratio		 1.79 1.47 1.33 1.34 1.27 1.47 1.45 1.40 1.42 1.38 1.44
Compound Leverage Factor		 1.94 1.53 1.36 1.33 1.24 1.45 1.44 1.37 1.28 1.26 1.34
Debt to Total Capital		 32.41% 12.75% 16.10% 8.49% 9.35% 19.64% 0.00% 17.65% 20.90% 19.63% 26.13%
Short-Term Debt to Total Capital		 13.42% 9.76% 0.00% 1.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 18.99% 2.98% 16.10% 7.10% 9.35% 19.64% 0.00% 17.65% 20.90% 19.63% 26.13%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 67.59% 87.25% 83.90% 91.51% 90.65% 80.36% 100.00% 82.35% 79.10% 80.37% 73.87%
Debt to EBITDA		 -0.68 -0.35 -0.36 -0.23 -0.26 -0.56 0.00 -0.38 -0.59 -0.40 -0.53
Net Debt to EBITDA		 1.73 2.65 2.10 2.84 2.40 2.32 0.00 1.24 1.33 1.18 0.95
Long-Term Debt to EBITDA		 -0.40 -0.08 -0.36 -0.19 -0.26 -0.56 0.00 -0.38 -0.59 -0.40 -0.53
Debt to NOPAT		 -0.94 -0.48 -0.50 -0.32 -0.36 -1.05 0.00 -0.48 -0.73 -0.53 -0.71
Net Debt to NOPAT		 2.39 3.64 2.93 3.97 3.35 4.34 0.00 1.56 1.64 1.55 1.28
Long-Term Debt to NOPAT		 -0.55 -0.11 -0.50 -0.27 -0.36 -1.05 0.00 -0.48 -0.73 -0.53 -0.71
Altman Z-Score		 -1.38 -0.32 2.29 7.57 13.38 18.65 12.66 0.02 -2.09 -4.32 -6.98
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.88 6.14 9.29 7.53 8.17 5.78 7.79 4.40 8.48 7.58 5.79
Quick Ratio		 4.82 6.07 9.14 7.39 7.96 5.71 7.68 4.16 8.11 7.34 5.67
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -12 -23 -29 -30 -105 -76 -119 -400 -136 -87 -89
Operating Cash Flow to CapEx		 -1,228.10% -6,793.39% -2,134.32% -1,678.25% -1,124.75% -795.40% -321.22% -697.88% -2,149.57% -16,832.05% -1,897.41%
Free Cash Flow to Firm to Interest Expense		 -5.44 -13.83 -20.78 -17.78 -60.10 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -8.29 -18.22 -26.56 -22.79 -47.47 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -8.96 -18.49 -27.81 -24.15 -51.70 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.04 0.05 0.04 0.03 0.04 0.07 0.07 0.12 0.10 0.03 0.02
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 7.87 4.08 3.15 5.08 2.98
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.45 2.35 1.99 1.24 1.29 1.44 0.90 0.96 0.61 0.17 0.11
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 46.38 89.37 115.78 71.83 122.33
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 46.38 89.37 115.78 71.83 122.33
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -8.66 -8.39 -9.07 -26 8.90 -4.53 -38 146 150 90 75
Invested Capital Turnover		 -0.49 -0.52 -0.47 -0.27 -1.26 14.39 -2.64 1.77 0.43 0.11 0.08
Increase / (Decrease) in Invested Capital		 -7.38 0.26 -0.68 -17 35 -13 -33 184 3.14 -60 -15
Enterprise Value (EV)		 50 4.29 168 641 1,243 7,544 4,871 643 150 -41 -18
Market Capitalization		 97 86 255 828 1,479 7,933 5,587 980 369 188 113
Book Value per Share		 $1.32 $2.14 $1.85 $2.49 $3.24 $4.41 $7.11 $4.98 $3.74 $2.80 $1.80
Tangible Book Value per Share		 $1.32 $2.14 $1.85 $2.49 $3.24 $4.41 $7.11 $4.98 $3.74 $2.80 $1.80
Total Capital		 56 84 92 175 270 478 679 588 466 397 280
Total Debt		 18 11 15 15 25 94 0.00 104 97 78 73
Total Long-Term Debt		 11 2.50 15 12 25 94 0.00 104 97 78 73
Net Debt		 -47 -81 -86 -186 -236 -389 -717 -337 -219 -229 -132
Capital Expenditures (CapEx)		 1.50 0.44 1.73 2.30 7.40 4.93 51 36 6.15 0.73 5.59
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.05 -5.79 -9.52 -21 -22 -74 -64 -48 -23 -26 -31
Debt-free Net Working Capital (DFNWC)		 60 86 92 180 199 409 552 388 292 253 173
Net Working Capital (NWC)		 52 78 92 178 199 409 552 388 292 253 173
Net Nonoperating Expense (NNE)		 11 11 13 20 28 84 60 66 28 39 33
Net Nonoperating Obligations (NNO)		 -47 -82 -86 -186 -236 -389 -717 -337 -219 -229 -132
Total Depreciation and Amortization (D&A)		 0.86 1.19 1.03 0.99 2.45 7.87 15 16 14 9.88 9.30
Debt-free, Cash-free Net Working Capital to Revenue		 -207.65% -131.51% -231.95% -440.15% -209.47% -235.91% -114.21% -50.06% -35.78% -188.40% -466.81%
Debt-free Net Working Capital to Revenue		 2,458.29% 1,961.00% 2,229.59% 3,805.30% 1,865.95% 1,300.37% 988.66% 402.93% 460.31% 1,858.90% 2,597.55%
Net Working Capital to Revenue		 2,147.72% 1,775.01% 2,229.59% 3,753.86% 1,865.95% 1,300.37% 988.66% 402.93% 460.31% 1,858.90% 2,597.55%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.18) ($1.05) ($1.02) ($1.19) ($1.44) ($2.10) ($2.24) ($2.91) ($1.64) ($1.64) ($1.15)
Adjusted Weighted Average Basic Shares Outstanding		 28.86M 41.39M 52.77M 65.00M 75.93M 93.78M 96.43M 96.83M 98.41M 113.69M 118.79M
Adjusted Diluted Earnings per Share		 ($1.18) ($1.05) ($1.02) ($1.19) ($1.44) ($2.10) ($2.24) ($2.91) ($1.64) ($1.64) ($1.15)
Adjusted Weighted Average Diluted Shares Outstanding		 28.86M 41.39M 52.77M 65.00M 75.93M 93.78M 96.43M 96.83M 98.41M 113.69M 118.79M
Adjusted Basic & Diluted Earnings per Share		 ($1.18) ($1.05) ($1.02) ($1.19) ($1.44) ($2.10) ($2.24) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 25.48M 31.75M 41.98M 56.20M 68.19M 82.39M 94.75M 98.16M 99.24M 114.60M 116.26M
Normalized Net Operating Profit after Tax (NOPAT)		 -19 -22 -29 -47 -71 -90 -152 -216 -133 -137 -103
Normalized NOPAT Margin		 -799.98% -508.27% -718.16% -990.81% -660.20% -285.23% -271.99% -224.16% -209.90% -1,004.16% -1,555.71%
Pre Tax Income Margin		 -1,233.73% -760.15% -1,046.08% -1,394.60% -919.00% -551.59% -379.89% -292.55% -253.30% -1,366.46% -2,051.08%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -12.51 -19.53 -30.39 -39.27 -57.49 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -8.76 -13.67 -21.28 -27.69 -40.24 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -13.19 -19.79 -31.64 -40.63 -61.71 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -9.43 -13.94 -22.52 -29.05 -44.47 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Fate Therapeutics

This table displays calculated financial ratios and metrics derived from Fate Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 98,562,432.00 98,601,966.00 98,601,966.00 113,831,969.00 113,877,884.00 - 114,597,425.00 114,633,022.00 115,329,697.00 115,352,289.00 116,263,459.00
DEI Adjusted Shares Outstanding		 98,562,432.00 98,601,966.00 98,601,966.00 113,831,969.00 113,877,884.00 - 114,597,425.00 114,633,022.00 115,329,697.00 115,352,289.00 116,263,459.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.46 -0.45 -0.49 -0.34 -0.42 - -0.33 -0.30 -0.28 -0.28 -0.27
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -87.02% -96.22% -96.74% 625.83% 58.13% 10.98% -15.38% -71.84% -43.36% -26.40% -20.26%
EBITDA Growth		 40.84% 14.60% -270.56% 25.81% -2.73% -13.29% 22.56% 16.23% 34.80% 38.55% 20.05%
EBIT Growth		 41.57% 18.07% -131.02% 24.30% -4.51% -15.43% 21.47% 14.48% 33.18% 38.25% 19.23%
NOPAT Growth		 40.64% 25.37% -78.61% 27.94% -2.14% -28.44% 19.17% 18.00% 33.68% 43.77% 20.06%
Net Income Growth		 45.95% 21.72% -154.25% 27.16% -5.55% -18.20% 21.63% 11.34% 32.36% 37.93% 17.03%
EPS Growth		 46.51% 22.41% -147.37% 38.89% 13.04% 2.22% 31.91% 12.12% 32.50% 38.64% 18.75%
Operating Cash Flow Growth		 30.47% 51.40% -15.56% -13.38% 23.13% 24.12% -1.38% 23.89% 17.15% 16.13% 8.83%
Free Cash Flow Firm Growth		 37.19% 83.95% 100.39% 80.87% 89.83% 144.98% 2,621.80% 243.54% 296.30% -159.20% -181.46%
Invested Capital Growth		 46.04% 2.15% -21.64% -9.30% -18.51% -39.95% -29.21% -36.55% -33.14% -16.15% -16.82%
Revenue Q/Q Growth		 108.36% -13.79% 14.86% 251.79% -54.61% -39.49% -12.42% 17.07% -8.70% -21.37% -5.11%
EBITDA Q/Q Growth		 12.99% 3.78% -7.32% 17.43% -20.48% -6.11% 26.64% 10.68% 6.23% -0.01% 4.56%
EBIT Q/Q Growth		 12.72% 2.67% -7.45% 17.06% -20.49% -7.50% 26.90% 9.68% 5.86% 0.66% 4.38%
NOPAT Q/Q Growth		 18.04% 6.25% -6.23% 11.72% -16.18% -17.89% 33.15% 10.45% 6.04% 0.04% 4.96%
Net Income Q/Q Growth		 14.38% 2.32% -8.80% 19.95% -24.07% -9.39% 27.86% 9.44% 5.34% -0.38% 3.59%
EPS Q/Q Growth		 14.81% 2.17% -4.44% 29.79% -21.21% -10.00% 27.27% 9.38% 6.90% 0.00% 3.70%
Operating Cash Flow Q/Q Growth		 -34.32% 4.27% 8.97% 3.13% 8.94% 5.51% -21.62% 27.28% 0.87% 4.35% -32.20%
Free Cash Flow Firm Q/Q Growth		 7.47% 56.10% 100.93% -5,189.92% 50.80% 294.12% -44.01% 168.42% -32.71% -158.54% 22.96%
Invested Capital Q/Q Growth		 -0.70% -1.58% -12.68% 6.29% -10.79% -27.47% 2.93% -4.73% -5.99% -9.04% 2.11%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -2,488.89% -2,777.86% -2,595.48% -609.21% -1,616.95% -2,835.70% -2,375.20% -1,812.27% -1,861.46% -2,367.57% -2,381.37%
Operating Margin		 -2,637.81% -2,868.44% -2,652.88% -665.73% -1,703.87% -3,319.78% -2,534.07% -1,938.54% -1,995.12% -2,536.23% -2,540.42%
EBIT Margin		 -2,565.17% -2,895.94% -2,709.25% -638.72% -1,695.38% -3,012.20% -2,514.24% -1,939.75% -2,000.29% -2,526.95% -2,546.57%
Profit (Net Income) Margin		 -2,323.56% -2,632.58% -2,493.71% -567.44% -1,551.01% -2,803.92% -2,309.45% -1,786.58% -1,852.38% -2,364.79% -2,402.85%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 90.58% 90.91% 92.04% 88.84% 91.48% 93.09% 91.85% 92.10% 92.61% 93.58% 94.36%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -1,531.51% -861.65% -80.91% -39.32% -116.26% -264.55% -212.03% -101.28% -96.44% -142.85% -132.60%
ROIC Less NNEP Spread (ROIC-NNEP)		 -1,528.72% -857.89% -76.86% -36.79% -111.76% -260.56% -208.47% -97.48% -92.36% -138.38% -127.16%
Return on Net Nonoperating Assets (RNNOA)		 1,103.51% 559.86% 51.57% 23.92% 71.46% 169.76% 143.37% 63.87% 60.35% 94.91% 81.14%
Return on Equity (ROE)		 -428.00% -301.79% -29.34% -15.40% -44.80% -94.80% -68.65% -37.41% -36.09% -47.94% -51.45%
Cash Return on Invested Capital (CROIC)		 -150.50% -92.20% -76.00% -84.00% -79.36% -73.01% -91.59% -73.94% -78.62% -107.61% -96.86%
Operating Return on Assets (OROA)		 -421.39% -303.67% -29.25% -14.13% -43.89% -86.72% -69.23% -36.49% -34.05% -44.22% -47.06%
Return on Assets (ROA)		 -381.70% -276.05% -26.92% -12.55% -40.16% -80.73% -63.59% -33.61% -31.53% -41.38% -44.40%
Return on Common Equity (ROCE)		 -428.00% -301.79% -29.34% -15.40% -44.80% -94.80% -68.65% -37.41% -36.09% -47.94% -51.45%
Return on Equity Simple (ROE_SIMPLE)		 -42.99% 0.00% -44.60% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -36 -34 -36 -32 -37 -43 -29 -26 -24 -24 -23
NOPAT Margin		 -1,846.47% -2,007.91% -1,857.02% -466.01% -1,192.71% -2,323.85% -1,773.85% -1,356.98% -1,396.58% -1,775.36% -1,778.29%
Net Nonoperating Expense Percent (NNEP)		 -2.79% -3.76% -4.04% -2.53% -4.50% -3.99% -3.55% -3.80% -4.07% -4.47% -5.43%
Return On Investment Capital (ROIC_SIMPLE)		 - -7.23% -6.85% -6.43% -8.07% -10.90% -7.91% -7.68% -7.88% -8.67% -9.18%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 974.69% 1,070.11% 1,083.38% 254.74% 676.68% 820.54% 845.49% 600.16% 611.03% 779.04% 738.72%
R&D to Revenue		 1,763.12% 1,898.33% 1,669.51% 510.99% 1,127.20% 1,806.94% 1,788.58% 1,438.38% 1,484.09% 1,857.20% 1,901.69%
Operating Expenses to Revenue		 2,737.81% 2,968.44% 2,752.88% 765.73% 1,803.87% 3,419.78% 2,634.07% 2,038.54% 2,095.12% 2,636.23% 2,640.42%
Earnings before Interest and Taxes (EBIT)		 -50 -49 -52 -43 -52 -56 -41 -37 -35 -35 -33
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -48 -47 -50 -41 -50 -53 -39 -35 -32 -32 -31
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.52 1.00 1.70 0.94 1.10 0.59 0.31 0.49 0.62 0.55 0.78
Price to Tangible Book Value (P/TBV)		 0.52 1.00 1.70 0.94 1.10 0.59 0.31 0.49 0.62 0.55 0.78
Price to Revenue (P/Rev)		 1.97 5.80 111.72 30.31 29.64 13.79 6.79 15.16 20.36 17.05 22.09
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 1.00 3.28 0.83 1.29 0.00 0.00 0.00 0.00 0.00 0.48
Enterprise Value to Revenue (EV/Rev)		 0.00 2.36 66.11 9.36 11.91 0.00 0.00 0.00 0.00 0.00 5.82
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.25 0.26 0.22 0.24 0.25 0.24 0.27 0.29 0.32 0.35 0.40
Long-Term Debt to Equity		 0.25 0.26 0.22 0.24 0.25 0.24 0.27 0.29 0.32 0.35 0.40
Financial Leverage		 -0.72 -0.65 -0.67 -0.65 -0.64 -0.65 -0.69 -0.66 -0.65 -0.69 -0.64
Leverage Ratio		 1.40 1.42 1.33 1.33 1.36 1.38 1.36 1.37 1.41 1.44 1.46
Compound Leverage Factor		 1.27 1.29 1.22 1.19 1.24 1.28 1.25 1.26 1.30 1.35 1.38
Debt to Total Capital		 19.73% 20.90% 18.33% 19.13% 20.26% 19.63% 21.03% 22.45% 24.14% 26.13% 28.62%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 19.73% 20.90% 18.33% 19.13% 20.26% 19.63% 21.03% 22.45% 24.14% 26.13% 28.62%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 80.27% 79.10% 81.66% 80.87% 79.73% 80.37% 78.97% 77.55% 75.86% 73.87% 71.38%
Debt to EBITDA		 -0.58 -0.59 -0.48 -0.50 -0.49 -0.40 -0.42 -0.43 -0.47 -0.53 -0.55
Net Debt to EBITDA		 1.46 1.33 1.47 1.39 1.27 1.18 1.07 0.99 0.95 0.95 0.79
Long-Term Debt to EBITDA		 -0.58 -0.59 -0.48 -0.50 -0.49 -0.40 -0.42 -0.43 -0.47 -0.53 -0.55
Debt to NOPAT		 -0.68 -0.73 -0.64 -0.69 -0.67 -0.53 -0.55 -0.56 -0.61 -0.71 -0.74
Net Debt to NOPAT		 1.73 1.64 1.98 1.89 1.73 1.55 1.40 1.29 1.24 1.28 1.05
Long-Term Debt to NOPAT		 -0.68 -0.73 -0.64 -0.69 -0.67 -0.53 -0.55 -0.56 -0.61 -0.71 -0.74
Altman Z-Score		 -1.51 -1.24 0.37 -1.34 -1.66 -3.22 -4.19 -4.49 -4.96 -5.81 -6.63
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 8.81 8.48 8.69 9.18 8.29 7.58 8.81 8.04 7.87 5.79 5.85
Quick Ratio		 8.50 8.11 8.47 8.79 8.04 7.34 8.62 7.82 7.69 5.67 5.72
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -84 -37 0.34 -17 -8.52 17 9.27 25 17 -9.80 -7.55
Operating Cash Flow to CapEx		 -6,773.98% -20,241.44% -38,779.07% -63,345.10% -5,943.23% -28,366.33% -2,826.84% -1,805.21% -1,107.91% -2,441.26% -12,896.23%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.16 0.10 0.01 0.02 0.03 0.03 0.03 0.02 0.02 0.02 0.02
Accounts Receivable Turnover		 18.06 3.15 0.90 6.35 4.75 5.08 8.17 6.93 2.97 2.98 4.06
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.01 0.61 0.06 0.13 0.15 0.17 0.17 0.11 0.10 0.11 0.11
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 20.21 115.78 404.50 57.50 76.88 71.83 44.67 52.64 122.97 122.33 89.86
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 20.21 115.78 404.50 57.50 76.88 71.83 44.67 52.64 122.97 122.33 89.86
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 152 150 131 139 124 90 92 88 83 75 77
Invested Capital Turnover		 0.83 0.43 0.04 0.08 0.10 0.11 0.12 0.07 0.07 0.08 0.07
Increase / (Decrease) in Invested Capital		 48 3.14 -36 -14 -28 -60 -38 -51 -41 -15 -16
Enterprise Value (EV)		 -42 150 428 115 160 -41 -105 -45 -5.92 -18 37
Market Capitalization		 209 369 724 373 399 188 91 128 145 113 140
Book Value per Share		 $4.09 $3.74 $4.21 $3.49 $3.18 $2.80 $2.52 $2.28 $2.03 $1.80 $1.55
Tangible Book Value per Share		 $4.09 $3.74 $4.21 $3.49 $3.18 $2.80 $2.52 $2.28 $2.03 $1.80 $1.55
Total Capital		 502 466 522 491 454 397 365 337 309 280 252
Total Debt		 99 97 96 94 92 78 77 76 74 73 72
Total Long-Term Debt		 99 97 96 94 92 78 77 76 74 73 72
Net Debt		 -251 -219 -295 -258 -238 -229 -196 -173 -151 -132 -103
Capital Expenditures (CapEx)		 0.57 0.18 0.09 0.05 0.50 0.10 1.20 1.36 2.20 0.96 0.24
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -27 -23 -35 -20 -24 -26 -20 -21 -22 -31 -26
Debt-free Net Working Capital (DFNWC)		 323 292 349 285 273 253 220 202 193 173 149
Net Working Capital (NWC)		 323 292 349 285 273 253 220 202 193 173 149
Net Nonoperating Expense (NNE)		 9.27 10 12 6.87 11 8.93 8.73 8.19 7.94 8.07 8.11
Net Nonoperating Obligations (NNO)		 -251 -219 -295 -258 -238 -229 -196 -173 -151 -132 -103
Total Depreciation and Amortization (D&A)		 1.48 1.98 2.19 2.00 2.41 3.28 2.27 2.43 2.42 2.18 2.15
Debt-free, Cash-free Net Working Capital to Revenue		 -25.32% -35.78% -533.16% -164.68% -178.86% -188.40% -152.73% -249.19% -312.22% -466.81% -411.42%
Debt-free Net Working Capital to Revenue		 303.96% 460.31% 5,387.56% 2,310.59% 2,029.24% 1,858.90% 1,650.23% 2,381.63% 2,706.18% 2,597.55% 2,356.51%
Net Working Capital to Revenue		 303.96% 460.31% 5,387.56% 2,310.59% 2,029.24% 1,858.90% 1,650.23% 2,381.63% 2,706.18% 2,597.55% 2,356.51%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.46) ($0.45) ($0.47) ($0.33) ($0.40) ($0.44) ($0.32) ($0.29) ($0.27) ($0.27) ($0.26)
Adjusted Weighted Average Basic Shares Outstanding		 98.57M 98.41M 101.10M 117.47M 117.77M 113.69M 118.38M 118.53M 119.00M 118.79M 120.03M
Adjusted Diluted Earnings per Share		 ($0.46) ($0.45) ($0.47) ($0.33) ($0.40) ($0.44) ($0.32) ($0.29) ($0.27) ($0.27) ($0.26)
Adjusted Weighted Average Diluted Shares Outstanding		 98.57M 98.41M 101.10M 117.47M 117.77M 113.69M 118.38M 118.53M 119.00M 118.79M 120.03M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 98.60M 99.24M 113.83M 113.88M 113.89M 114.60M 114.63M 115.33M 115.35M 116.26M 116.56M
Normalized Net Operating Profit after Tax (NOPAT)		 -36 -34 -36 -32 -37 -43 -29 -26 -24 -24 -23
Normalized NOPAT Margin		 -1,846.47% -2,007.91% -1,857.02% -466.01% -1,192.71% -2,323.85% -1,773.85% -1,356.98% -1,396.58% -1,775.36% -1,778.29%
Pre Tax Income Margin		 -2,323.56% -2,632.58% -2,493.71% -567.44% -1,551.01% -2,803.92% -2,309.45% -1,786.58% -1,852.38% -2,364.79% -2,402.85%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Fate Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Fate Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Fate Therapeutics' net income appears to be on an upward trend, with a most recent value of -$136.32 million in 2025, rising from -$29.99 million in 2015. The previous period was -$186.26 million in 2024. See where experts think Fate Therapeutics is headed by visiting Fate Therapeutics' forecast page.

Fate Therapeutics' total operating income in 2025 was -$147.70 million, based on the following breakdown:
  • Total Gross Profit: $6.65 million
  • Total Operating Expenses: $154.35 million

Over the last 10 years, Fate Therapeutics' total revenue changed from $2.43 million in 2015 to $6.65 million in 2025, a change of 173.4%.

Fate Therapeutics' total liabilities were at $111.75 million at the end of 2025, a 8.4% decrease from 2024, and a 273.5% increase since 2015.

In the past 10 years, Fate Therapeutics' cash and equivalents has ranged from $36.06 million in 2024 to $190.51 million in 2018, and is currently $46.63 million as of their latest financial filing in 2025.

Over the last 10 years, Fate Therapeutics' book value per share changed from 1.32 in 2015 to 1.80 in 2025, a change of 35.6%.


Related Companies

Financial statements for NASDAQ:FATE last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel